EHA 2021 VIRTUAL SCIENTIFIC PROGRAM JUNE 9–17, 2021
Bristol Myers Squibb Compendium of presentations Click on a therapeutic area to see a list of scheduled presentations
Table of Contents
Lymphoma
Multiple Myeloma
Myeloid Lymphoma
NON-HODGKIN LYMPHOMA
Poster Presentations
Presentation #EP539: Clinical Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma Receiving Third-Line Therapy: A Multicenter, Retrospective, Real-world Study in the United Kingdom Lead Author and Presenter: Christopher Fox, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom Session: Aggressive Non-Hodgkin lymphoma - Clinical
Presentation #EP541: OUTREACH: Preliminary Safety & Efficacy Results From a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Non-university Setting Lead Author and Presenter: John Godwin, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR, United States Session: Aggressive Non-Hodgkin lymphoma - Clinical
Presentation #EP1165: Systematic Literature Review (SLR) of the Efficacy and Safety of Second-Line (2L) Treatments for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Lead Author and Presenter: Fei Fei Liu, Bristol Myers Squibb, Princeton, NJ, United States Session: Quality of Life, Palliative Care, Ethics and Health Economics
Presentation #EP1169: Use of Chimeric Antigen Receptor T cell Therapies in Patients With Large B-Cell Lymphoma in the Real-World Setting: Systematic Literature Review Lead Author and Presenter: Fei Fei Liu, Bristol Myers Squibb, Princeton, NJ, United States Session: Quality of Life, Palliative Care, Ethics and Health Economics
HODGKIN LYMPHOMA
Poster Presentation
Presentation #EP1178: Targeted Landscape Review for Understanding Lymphoma Patient-Reported Outcome Assessment in the Era of Emerging Therapies Lead Author and Presenter: Stacie Hudgens, Regulatory and Access, Clinical Outcomes Solutions, Tucson, AZ, United States Session: Quality of Life, Palliative Care, Ethics and Health Economics Multiple Myeloma
MULTIPLE MYELOMA
Oral Presentation
Presentation #S187: Iberdomide (IBER) in Combination With Dexamethasone (DEX) and Daratumumab (DARA), Bortezomib (BORT), or Carfilzomib (CFX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Lead Author and Presenter: Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA, United States Session: New Diagnostic and Therapeutic Approaches in Multiple Myeloma and AL Amyloidosis EHA Thematic Day Q&A: June 14, 2021 4:00 PM-4:45 PM (CEST) Virtual Room 3
Poster Presentations
Presentation #EP747: Anakinra Prophylaxis in Patients With Relapsed/Refractory Multiple Myeloma Receiving Orvacabtagene Autoleucel (orva-cel) Lead Author and Presenter: Luciano Costa, University of Alabama Birmingham, Birmingham, AL, United States Session: Gene Therapy, Cellular Immunotherapy and Vaccination - Clinical
Presentation #EP984: Characteristics of Neurotoxicity Associated With Idecabtagene Vicleucel (Ide-cel, bb2121) in Patients With Relapsed and Refractory Multiple Myeloma in the Pivotal Phase 2 KarMMa Study Lead Author and Presenter: Salomon Manier, Department of Hematologic Malignancies, Lille University Hospital, Lille, France Session: Myeloma and Other Monoclonal Gammopathies - Clinical
Presentation #EP988: Pomalidomide, Bortezomib, and Dexamethasone After 1 Prior Line of Therapy in Relapsed or Refractory Multiple Myeloma: A Safety Subanalysis of the Phase 3 OPTIMISMM Trial Lead Author and Presenter: Katja Weisel, Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Session: Myeloma and Other Monoclonal Gammopathies - Clinical Presentation #EP1009: Idecabtagene Vicleucel (Ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in Patients With Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results Lead Author and Presenter: Albert Oriol, Institut Josep Carreras and Institut Catala d'Oncolgia, Hospital Germans Trias I Pujol, Badalona, Spain Session: Myeloma and Other Monoclonal Gammopathies - Clinical
Presentation #EP1013: A Meta-analysis of Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed or Refractory Multiple Myeloma After Lenalidomide Exposure Lead Author and Presenter: Faith E. Davies, NYU Grossman School of Medicine, Clinical Myeloma Program, Perlmutter Cancer Center, New York, NY, United States Session: Myeloma and Other Monoclonal Gammopathies - Clinical
Presentation #EP1019: Pomalidomide, Dexamethasone, and Daratumumab in Relapsed Refractory Multiple Myeloma (MM-014 Phase 2 Trial): A Subanalysis of Patients Previously Treated With Lenalidomide and a Proteasome Inhibitor Lead Author and Presenter: Nizar J. Bahlis, Tom Baker Cancer Centre, Calgary, Canada Session: Myeloma and Other Monoclonal Gammopathies - Clinical
Publication Only
Publication #PB1673: Real-World Treatment Patterns in Clinical Outcomes in Patients With Multiple Myeloma in Different Geographical Regions: Findings From a Systematic Literature Review Lead Author: Elena Zamangi, University of Bologna, Bologna, Italy Myeloid
-THALASSEMIA
Oral Presentation
Presentation #S101: The BEYOND Study: Results of a Phase 2, Double-Blind, Randomized, Placebo- Controlled Multicenter Study of Luspatercept in Adult Patients With Non-transfusion Dependent Beta-Thalassemia Lead Author and Presenter: Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon Session: Presidential Symposium; June 11, 2021 4:15 PM-4:30 PM (CEST) Virtual Room 1
Poster Presentations
Presentation #EP1304: Fewer Red Blood Cell Transfusion Units and Visits Across Baseline Transfusion Burden Levels in Patients With Beta-Thalassemia Treated With Luspatercept in the Phase 3 BELIEVE Trial Lead Author and Presenter: Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon Session: Thalassemias
Presentation #EP1305: Long-Term Efficacy and Safety Outcomes in the Phase 2 Study of Luspatercept in β-thalassemia Lead Author and Presenter: Antonio Piga, University of Turin, Turin, Italy Session: Thalassemias
Presentation #EP1306: Benefit of Continuing Therapy With Luspatercept in Patients With Beta- Thalassemia Who Do Not Achieve ≥33% Reduction in Red Blood Cell (RBC) Transfusion Burden (TB) in Weeks 13-24 in the BELIEVE Trial Lead Author and Presenter: Antonio Piga, University of Turin, Turin, Italy Session: Thalassemias
Presentation #EP1315: Quantifying the Healthcare Resource Use and Clinical Outcomes of Patients With Beta Thalassemia in England Lead Author and Presenter: James Farrell, Bristol Myers Squibb, Princeton, NJ, United States Session: Thalassemias MYELODYSPLASTIC SYNDROME
Poster Presentations
Presentation #EP915: Benefit of Continuing Luspatercept Therapy in Patients With Lower-Risk Myelodysplastic Syndromes Who Did Not Achieve Red Blood Cell Transfusion Independence by Week 25 in the MEDALIST Study Lead Author and Presenter: Ulrich Germing, University Hospital of Düsseldorf, Düsseldorf, Germany Session: Myelodysplastic Syndromes - Clinical
Presentation #EP920: Luspatercept Reduces Red Blood Cell Transfusions in Patients With Lower-Risk Myelodysplastic Syndromes Regardless of Baseline Transfusion Burden in the MEDALIST Study Lead Author and Presenter: Guillermo Garcia-Manero, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Session: Myelodysplastic Syndromes - Clinical
Presentation #EP930: Quantifying the Healthcare Resource Use and Clinical Outcomes of Patients With Myelodysplastic Syndrome With Ringed Sideroblasts in England Lead Author and Presenter: James Farrell, Bristol Myers Squibb, Princeton, NJ, United States Session: Myelodysplastic Syndromes - Clinical
Presentation #EP1182: Health-Related Quality of Life (HRQoL) in Patients (Pts) With Myelodysplastic Syndromes (MDS) in the CONNECT® Myeloid Disease Registry Lead Author: Dennis A. Revicki, Outcomes Research Consulting, Sarasota, FL, United States Session: Quality of Life, Palliative Care, Ethics and Health Economics
Publication Only
Publication #PB1619: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to Lower-Risk MDS in ESA-Naive Patients Requiring RBC Transfusions (the COMMANDS trial) Lead Author: Matteo Della Porta, Cancer Center IRCCS Humanitas Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, Italy ACUTE MYELOID LEUKEMIA
Oral Presentations
Presentation #S131: Survival Outcomes From the QUAZAR AML-001 Trial With Oral Azacitidine for Patients With Acute Myeloid Leukemia in Remission by Disease Subtype, Cytogenetic Risk, and NPM1 Mutation Status at Diagnosis Lead Author and Presenter: Hartmut Döhner, Universitätsklinikum Ulm, Ulm, Germany Session: AML Classification EHA Thematic Day Q&A: June 17, 2021 7:45 PM-8:30 PM (CEST) Virtual Room 2
Presentation #S311: Estimated Hospitalization-Related Costs With Oral Azacitidine (Oral-AZA) vs Placebo (PBO) for Remission Maintenance in Patients With Acute Myeloid Leukemia (AML) in Spain and the United Kingdom (UK) Lead Author: Christopher Pocock, Kemp and Canterbury Hospital, Canterbury, United Kingdom Presenter: Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy Session: Patient's Voice and Health Outcomes in Hematology EHA Thematic Day Q&A: June 15, 2021 8:45 PM-9:30 PM (CEST) Virtual Room 1
Poster Presentations
Presentation #EP428: Prognostic Factors of Overall and Relapse-Free Survival for Patients With Acute Myeloid Leukemia (AML) in Remission: Multivariate Analyses From the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Lead Author and Presenter: Gail Roboz, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States Session: Acute Myeloid Leukemia - Clinical
Presentation #EP445: Hematologic Adverse Events and Management Strategies for Patients With Acute Myeloid Leukemia (AML) in First Remission Receiving Oral Azacitidine (Oral-AZA) in the Phase 3 QUAZAR AML-001 Trial Lead Author and Presenter: Farhad Ravandi, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Session: Acute Myeloid Leukemia - Clinical
Presentation #EP446: Comparative Efficacy of Oral Versus Injectable Azacitidine in Patients With AML in First Remission After Intensive Chemotherapy: An Indirect Treatment Comparison (Sub-Analysis Update) Lead Author and Presenter: Clara Chen, Bristol Myers Squibb, Princeton, NJ, United States Session: Acute Myeloid Leukemia - Clinical Presentation #EP457: A Phase 3 Study of Enasidenib (ENA) Versus Conventional Care Regimens (CCR) in Older Patients With Late-Stage Mutant-IDH2 (MIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Lead Author and Presenter: Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Session: Acute Myeloid Leukemia - Clinical
Presentation #EP465: Updated Pharmacodynamic and Survival Outcomes From the AG221-AML-005 Trial of Enasidenib (ENA) Plus Azacitidine (AZA) in Patients With Mutant IDH2 Newly Diagnosed Acute Myeloid Leukemia (ND-AML) Lead Author and Presenter: Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Session: Acute Myeloid Leukemia - Clinical
Publication Only
Publication #PB1395: Systematic Literature Review of the Efficacy and Safety of Maintenance Therapies for Adults With Acute Myeloid Leukemia in Complete Remission Who Are Ineligible for Hematopoietic Stem Cell Transplant Lead Author: Beatrice Suero, Eversana, Burlington, ON, Canada
Publication #PB1398: Patient Preferences for Maintenance Therapy of Acute Myeloid Leukemia: A Discrete Choice Experiment Subanalysis of Patients in Germany and Italy Lead Author: Katelyn Cutts, Evidera, Bethesda, MD, United States
Publication #PB1406: European Guidelines and Real-World Evidence of Maintenance Treatments for Adults With Acute Myeloid Leukemia in First Complete Remission Lead Author: Moez Ahmed, Eversana, Burlington, ON, Canada MYELOFIBROSIS
Oral Presentation
Presentation #S203: Overall and Progression-Free Survival in Patients Treated With Fedratinib as First-Line Myelofibrosis (MF) Therapy and After Prior Ruxolitinib (RUX): Results From the JAKARTA and JAKARTA2 Trials Lead Author and Presenter: Claire Harrison, Guy's and St. Thomas' Hospital, London, United Kingdom Session: Therapies and Targets in MPN EHA Thematic Day Q&A: June 16, 2021 4:00 PM-4:45 PM (CEST) Virtual Room 2
Poster Presentation
Presentation #EP1062: Fedratinib Demonstrates Limited Suppression of T- and Natural Killer- (NK) Cell Activity Ex Vivo Compared With Ruxolitinib at Clinically Relevant Doses Lead Author and Presenter: Aarif Ahsan, Bristol Myers Squibb, Princeton, NJ, United States Session: Myeloproliferative Neoplasms - Biology & Translational Research
Publication Only
Publication #PB1702: Efficacy and Safety of Luspatercept Versus Placebo in Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring RBC Transfusions (INDEPENDENCE trial) Lead Author: Ruben Mesa, Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX, United States
CHRONIC MYELOID LEUKEMIA
Poster Presentation
Presentation #EP677: Effect of Comorbidities on Patient Responses With First-Line Dasatinib Versus Imatinib in Chronic Myeloid Leukemia in Chronic Phase: Exploratory Post Hoc Analysis of DASISION Lead Author and Presenter: Massimo Breccia, Sapienza University, Rome, Italy Session: Chronic Myeloid Leukemia - Clinical
© 2021 Bristol-Myers Squibb Company 6/21 NP-WWM-NA-0137 The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.